New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market by Product, Application, Geography - Global Forecast to 2025" - https://www.reportlinker.com/p04700208/?utm_source=GNW However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast periodBased on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019.
The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.
Oncology segment accounted for highest CAGRBased on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.In 2019, the oncology segment accounted for the highest growth rate.
This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.
Europe: The fastest-growing region regenerative medicine marketThe global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World.The North America region is projected to grow at the highest CAGR during the forecast period in 2019.
The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.
The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World 12%
Lits of companies Profiled in the Report: 3M (US) Allergan plc (Ireland) Amgen, Inc. (US) Aspect Biosystems (Canada) bluebird bio (US) Kite Pharma (US) Integra LifeSciences Holdings Corporation (US) MEDIPOST Co., Ltd. (South Korea) Medtronic plc (Ireland) Anterogen Co., Ltd. (South Korea) MiMedx Group (US) Misonix (US) Novartis AG (Switzerland) Organogenesis Inc. (US) Orthocell Limited (Australia) Corestem, Inc. (South Korea) Spark Therapeutics (US) APAC Biotech (India) Shenzhen Sibiono GeneTech Co., Ltd. (China) Smith & Nephew plc (UK) Stryker Corporation (US) Takeda Pharmaceutical Company Limited (Japan) Tego Science (South Korea) Vericel Corporation (US) Zimmer Biomet (US)
Research Coverage:This report provides a detailed picture of the global regenerative medicine market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.
This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.
Read the full report: https://www.reportlinker.com/p04700208/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
See the article here:
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments